U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Pleural Malignant Mesothelioma

MedGen UID:
163482
•Concept ID:
C0854891
•
Neoplastic Process
Synonyms: Malignant Pleural Mesothelioma Recurrent; Relapsed Malignant Mesothelioma of Pleura; Relapsed Malignant Mesothelioma of the Pleura; Relapsed Malignant Pleural Mesothelioma

Definition

The reemergence of pleural malignant mesothelioma after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Pleural Malignant Mesothelioma

Professional guidelines

PubMed

ERS/EACTS statement on the management of malignant pleural effusions.
Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, Subotic D, Astoul P, Licht P, Schmid R, Scherpereel A, Rahman NM, Cardillo G, Maskell NA
Eur Respir J 2018 Jul;52(1) Epub 2018 Jul 27 doi: 10.1183/13993003.00349-2018. PMID: 30054348
Current surgical treatment of malignant pleural mesothelioma.
Chihara K
Respir Investig 2018 Jul;56(4):265-266. Epub 2018 Jul 3 doi: 10.1016/j.resinv.2017.12.002. PMID: 29980443
Multimodality management of malignant pleural mesothelioma: introduction.
Sugarbaker DJ
Semin Thorac Cardiovasc Surg 2009 Summer;21(2):95-6. doi: 10.1053/j.semtcvs.2009.07.005. PMID: 19822279

Recent clinical studies

Etiology

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L, Lord J, Middleton C, Szlosarek P, Chan S, Gaba A, Darlison L, Wells-Jordan P, Richards C, Poile C, Lester JF, Griffiths G; CONFIRM trial investigators
Lancet Oncol 2021 Nov;22(11):1530-1540. Epub 2021 Oct 14 doi: 10.1016/S1470-2045(21)00471-X. PMID: 34656227Free PMC Article
Mesothelial Cysts.
Karpathiou G, Casteillo F, Dridi M, Peoc'h M
Am J Clin Pathol 2021 May 18;155(6):853-862. doi: 10.1093/ajcp/aqaa189. PMID: 33258870
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N
Lancet Oncol 2020 Jan;21(1):121-133. Epub 2019 Dec 4 doi: 10.1016/S1470-2045(19)30671-0. PMID: 31812554
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Ligeza-Poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G; French Cooperative Thoracic Intergroup
Lancet Oncol 2019 Feb;20(2):239-253. Epub 2019 Jan 16 doi: 10.1016/S1470-2045(18)30765-4. PMID: 30660609
ERS/EACTS statement on the management of malignant pleural effusions.
Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, Subotic D, Astoul P, Licht P, Schmid R, Scherpereel A, Rahman NM, Cardillo G, Maskell NA
Eur Respir J 2018 Jul;52(1) Epub 2018 Jul 27 doi: 10.1183/13993003.00349-2018. PMID: 30054348

Diagnosis

New developments in mesothelial pathology.
Churg A
Histopathology 2024 Jan;84(1):136-152. Epub 2023 Sep 11 doi: 10.1111/his.15007. PMID: 37694811
The cytologic diagnosis of mesothelioma: are we there yet?
Michael CW
J Am Soc Cytopathol 2023 Mar-Apr;12(2):89-104. Epub 2022 Dec 26 doi: 10.1016/j.jasc.2022.12.001. PMID: 36702736
Imaging of Malignant Pleural, Pericardial, and Peritoneal Mesothelioma.
Strange CD, Marom EM, Ahuja J, Shroff GS, Gladish GW, Carter BW, Truong MT
Adv Anat Pathol 2023 Jul 1;30(4):280-291. Epub 2022 Nov 18 doi: 10.1097/PAP.0000000000000386. PMID: 36395181
Solid papillary mesothelial tumor.
Churg A, Le Stang N, Dacic S, Pissaloux D, Begueret H, Dartigues P, Giusiano-Courcambeck S, Sequeiros R, Pairon JC, Tirode F, Galateau-Sallé F
Mod Pathol 2022 Jan;35(1):69-76. Epub 2021 Sep 3 doi: 10.1038/s41379-021-00899-3. PMID: 34480081
ERS/EACTS statement on the management of malignant pleural effusions.
Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, Subotic D, Astoul P, Licht P, Schmid R, Scherpereel A, Rahman NM, Cardillo G, Maskell NA
Eur Respir J 2018 Jul;52(1) Epub 2018 Jul 27 doi: 10.1183/13993003.00349-2018. PMID: 30054348

Therapy

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L, Lord J, Middleton C, Szlosarek P, Chan S, Gaba A, Darlison L, Wells-Jordan P, Richards C, Poile C, Lester JF, Griffiths G; CONFIRM trial investigators
Lancet Oncol 2021 Nov;22(11):1530-1540. Epub 2021 Oct 14 doi: 10.1016/S1470-2045(21)00471-X. PMID: 34656227Free PMC Article
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N
Lancet Oncol 2020 Jan;21(1):121-133. Epub 2019 Dec 4 doi: 10.1016/S1470-2045(19)30671-0. PMID: 31812554
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Ligeza-Poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G; French Cooperative Thoracic Intergroup
Lancet Oncol 2019 Feb;20(2):239-253. Epub 2019 Jan 16 doi: 10.1016/S1470-2045(18)30765-4. PMID: 30660609
ERS/EACTS statement on the management of malignant pleural effusions.
Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, Subotic D, Astoul P, Licht P, Schmid R, Scherpereel A, Rahman NM, Cardillo G, Maskell NA
Eur Respir J 2018 Jul;52(1) Epub 2018 Jul 27 doi: 10.1183/13993003.00349-2018. PMID: 30054348
Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma.
Marulli G, Faccioli E, Bellini A, Mammana M, Rea F
Expert Rev Respir Med 2017 Aug;11(8):649-660. Epub 2017 Jun 12 doi: 10.1080/17476348.2017.1338951. PMID: 28580813

Prognosis

Solid papillary mesothelial tumor.
Churg A, Le Stang N, Dacic S, Pissaloux D, Begueret H, Dartigues P, Giusiano-Courcambeck S, Sequeiros R, Pairon JC, Tirode F, Galateau-Sallé F
Mod Pathol 2022 Jan;35(1):69-76. Epub 2021 Sep 3 doi: 10.1038/s41379-021-00899-3. PMID: 34480081
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L, Lord J, Middleton C, Szlosarek P, Chan S, Gaba A, Darlison L, Wells-Jordan P, Richards C, Poile C, Lester JF, Griffiths G; CONFIRM trial investigators
Lancet Oncol 2021 Nov;22(11):1530-1540. Epub 2021 Oct 14 doi: 10.1016/S1470-2045(21)00471-X. PMID: 34656227Free PMC Article
Mesothelial Cysts.
Karpathiou G, Casteillo F, Dridi M, Peoc'h M
Am J Clin Pathol 2021 May 18;155(6):853-862. doi: 10.1093/ajcp/aqaa189. PMID: 33258870
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N
Lancet Oncol 2020 Jan;21(1):121-133. Epub 2019 Dec 4 doi: 10.1016/S1470-2045(19)30671-0. PMID: 31812554
ERS/EACTS statement on the management of malignant pleural effusions.
Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, Subotic D, Astoul P, Licht P, Schmid R, Scherpereel A, Rahman NM, Cardillo G, Maskell NA
Eur Respir J 2018 Jul;52(1) Epub 2018 Jul 27 doi: 10.1183/13993003.00349-2018. PMID: 30054348

Clinical prediction guides

New developments in mesothelial pathology.
Churg A
Histopathology 2024 Jan;84(1):136-152. Epub 2023 Sep 11 doi: 10.1111/his.15007. PMID: 37694811
Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape.
Dagogo-Jack I, Madison RW, Lennerz JK, Chen KT, Hopkins JF, Schrock AB, Ritterhouse LL, Lester A, Wharton KA Jr, Mino-Kenudson M, Danziger N, Hung YP, Mata DA, Ross JS
JCO Precis Oncol 2022 Jun;6:e2100422. doi: 10.1200/PO.21.00422. PMID: 35704798
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N
Lancet Oncol 2020 Jan;21(1):121-133. Epub 2019 Dec 4 doi: 10.1016/S1470-2045(19)30671-0. PMID: 31812554
ERS/EACTS statement on the management of malignant pleural effusions.
Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, Subotic D, Astoul P, Licht P, Schmid R, Scherpereel A, Rahman NM, Cardillo G, Maskell NA
Eur Respir J 2018 Jul;52(1) Epub 2018 Jul 27 doi: 10.1183/13993003.00349-2018. PMID: 30054348
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations.
Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, Gnad F, Nguyen TT, Jaiswal BS, Chirieac LR, Sciaranghella D, Dao N, Gustafson CE, Munir KJ, Hackney JA, Chaudhuri A, Gupta R, Guillory J, Toy K, Ha C, Chen YJ, Stinson J, Chaudhuri S, Zhang N, Wu TD, Sugarbaker DJ, de Sauvage FJ, Richards WG, Seshagiri S
Nat Genet 2016 Apr;48(4):407-16. Epub 2016 Feb 29 doi: 10.1038/ng.3520. PMID: 26928227

Recent systematic reviews

Extrapleural pneumonectomies for pleural mesothelioma.
Faccioli E, Bellini A, Mammana M, Monaci N, Schiavon M, Rea F
Expert Rev Respir Med 2020 Jan;14(1):67-79. Epub 2019 Nov 13 doi: 10.1080/17476348.2020.1688147. PMID: 31674841
A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.
Petrelli F, Ardito R, Conti B, Coinu A, Cabiddu M, Ghilardi M, Borgonovo K, Barni S, Ghidini A
Respir Med 2018 Aug;141:72-80. Epub 2018 Jun 30 doi: 10.1016/j.rmed.2018.06.026. PMID: 30053976
Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma.
Marulli G, Faccioli E, Bellini A, Mammana M, Rea F
Expert Rev Respir Med 2017 Aug;11(8):649-660. Epub 2017 Jun 12 doi: 10.1080/17476348.2017.1338951. PMID: 28580813
Malignant mesothelioma and central nervous system metastases. Report of two cases, pooled analysis, and systematic review.
Miller AC, Miettinen M, Schrump DS, Hassan R
Ann Am Thorac Soc 2014 Sep;11(7):1075-81. doi: 10.1513/AnnalsATS.201404-165BC. PMID: 25079105Free PMC Article
Systematic review of pleurectomy in the treatment of malignant pleural mesothelioma.
Cao C, Tian DH, Pataky KA, Yan TD
Lung Cancer 2013 Sep;81(3):319-327. Epub 2013 Jun 13 doi: 10.1016/j.lungcan.2013.04.024. PMID: 23769317

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...